Treatments

Immunotherapy: the newest promising treatment for cancer

 
 
Coris Shepard's lung cancer didn't respond to radiation or chemotherapy but he is now on a clinical trial at Mount Sinai Medical Center in Miami Beach that has shrunk some tumors and eliminated others in his left lung. Shepard is in the kitchen of his Aventura home.
Coris Shepard's lung cancer didn't respond to radiation or chemotherapy but he is now on a clinical trial at Mount Sinai Medical Center in Miami Beach that has shrunk some tumors and eliminated others in his left lung. Shepard is in the kitchen of his Aventura home.
MARICE COHN BAND / MIAMI HERALD STAFF

aveciana@MiamiHerald.com

Though radiation sent Coris Shepard to the hospital with a burned esophagus for 21 days, it did little to the tumors in his left lung. The chemotherapy that followed didn’t work either. In fact, the stubborn cancer actually grew in size.

At wit’s end and almost out of hope, he agreed to participate in a clinical trial testing a new drug at Mount Sinai Comprehensive Cancer Center in Miami Beach, a drug that would use his body’s immune system to fight the cancerous cells. In April, four months after beginning treatment, an MRI determined some tumors had shrunk and others had disappeared entirely.

“I was absolutely elated,” says Shepard, who spends summers in Aventura and the rest of the year in Philadelphia. “I’m more hopeful now because nothing else I had tried had actually worked.”

Shepard is participating in Phase 1 of the MedImmune PD-L1 study. Mount Sinai is one of only four centers in the country where this treatment is available. The first part of the trial targets kidney, lung and colon cancers as well as deadly skin cancers known as melanomas. Researchers hope to open the study to head and neck cancer patients later. Like Shepard, the patients participating in the research are ones who have tried conventional treatments without success.

Shepard received infusions of an experimental treatment that uses the power of our body’s immune system to attack the cancer. The drug appears to work in a deceptively simple way, but it has taken years of research for scientists to tease out the information they needed to get this far.

Scientists now know that cancer cells use a cloaking mechanism to make themselves invisible to our immune system. They do this by binding together two proteins. One protein is called PD-1, or programmed death 1, which sits on T-cells, known as the warrior cells of our immune system. The second is a PD-L1, or programmed death ligand 1, which sits on the surface of the cancer cell to shield it from an attack by the body’s immune system. The treatment Shepard received targets PD-L1.

With this “shield” gone from the cancer cells, the tumor can no longer hide from the body’s immune system.

Mount Sinai medical oncologist Dr. Jose Lutzky says initial results show that treatment has successfully shrunk tumors, but he also warns that the experiment is at a very early stage. Phase 1 of clinical trials seeks to increase the doses of a drug very slowly to determine the optimal amount that does the most good with the least harm

“There are many steps involved in this process and we’re just beginning to discover them,” he said. “While we are seeing significant tumor shrinkage, we’re trying to find the right dose. We also know that the blockage offered by the cancer cells is going to vary from tumor to tumor.”

The MedImmune PD-L1 study is not the only one targeting the protein that enables cancer cells to make themselves invisible to the body’s immune system. Other companies, including Merck, Bristol-Meyers Squibb and Genentech/Roche, are developing drugs that target either PD-L1 or the molecule that binds to it (PD-1).

This kind of unprecedented effort underscores the research community’s enthusiasm for immunotherapy as the most promising new treatment for cancer. In fact, several immunotherapy drugs still in the testing phase were the talk of the American Society of Clinical Oncology meeting in Chicago in June. These new agents spur the body’s natural immune system to go after cancer cells, just as they would do in the case of a bacterial infection. What’s more, the concept has already been shown to work in a range of cancers. Provenge, the first cancer immunotherapy, was approved in 2010 to treat prostate tumors and Yervoy, approved a year later, treats metastatic melanoma.

“We’ll be looking for even more progress in this area,” Lutzky said. “I don’t think I’ve been so hopeful as an oncologist in a long time.”

Across town another promising immunotherapy is being studied at the University of Miami’s Miller School of Medicine. At the lab of Dr. Glen Barber, professor and chair of the Cell Biology Department, scientists are researching how a therapeutic virus known as vesicular stomatitis virus, or VSV, is able to destroy cancer cells while leaving normal healthy cells intact.

“All cancer cells are extraordinarily sensitive to viruses,” Barber said. “They have some kind of defect in that respect.”

Using the knowledge that cancers are susceptible to virus replication and thus are easily killed after an infection, Barber and his team tested it first on animal cells. Result? Normal cells didn’t allow replication of the VSV, but cancer cells actually exploded and died as a result.

“The virus,” Barber explained, “replicates like a balloon and pops the cancer cell.”

In the process of eliminating the virus infection “the body responds by eating the virus-infected cells. It cleans up and attacks the cancer cells,” he added.

Tested initially in mice, rats and rhesus monkeys, VSV is now in Phase I trials for the treatment of liver cancer at UM, in conjunction with the Mayo Clinic in Rochester, Minn., and Scottsdale, Ariz. This means scientists are using “very low doses, very conservative treatment” to determine both efficacy and lack of toxicity. Patients also receive an immune stimulatory gene, interferon beta, within the virus.

While encouraged by the progress of the experiment, Barber warns that the public shouldn’t expect an overnight cure. “It’s a tremendously complicated process and we have so much to unravel,” said Barber, who is also associate director of Basic Research at Sylvester Comprehensive Cancer Center. “There’s a lot of work going on and it takes time.”

Read more Health stories from the Miami Herald

  • Ask Nancy

    How to choose an assisted living facility

    Q. I live in California and have a formerly independent, elderly father in Tamarac, who is deteriorating following a mild stroke and is becoming an increasing burden for his partner, who lives with him. He has an extensive support network of friends in South Florida and doesn't wish to relocate to California, where my brother and I could more easily support him. I need to find an assisted living facility (ALF) for him in the Tamarac area. I certainly intend to travel to Tamarac and inspect the facilities personally, but it would help me a great deal to have a starting point.

  • Legislature 2014

    Florida House votes to regulate e-cigarette sales

    State lawmakers took significant steps to prohibit the sale of electronic cigarettes to minors.

  • Sleep

    To sleep well, adjust what you eat — and when

    Sleep. Oh, to sleep. A good night’s sleep is often a struggle for more than half of American adults. And for occasional insomnia, there are good reasons to avoid using medications, whether over-the-counter or prescription.

Miami Herald

Join the
Discussion

The Miami Herald is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere on the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

The Miami Herald uses Facebook's commenting system. You need to log in with a Facebook account in order to comment. If you have questions about commenting with your Facebook account, click here.

Have a news tip? You can send it anonymously. Click here to send us your tip - or - consider joining the Public Insight Network and become a source for The Miami Herald and el Nuevo Herald.

Hide Comments

This affects comments on all stories.

Cancel OK

  • Marketplace

Today's Circulars

  • Quick Job Search

Enter Keyword(s) Enter City Select a State Select a Category